Mammalian Tolloid Metalloproteinase, and Not Matrix Metalloprotease 2 or Membrane Type 1 Metalloprotease, Processes Laminin-5 in Keratinocytes and Skin*

Dallas P. VeitchDagger , Pasi NokelainenDagger §, Kelly A. McGowanDagger , Thuong-Thuong NguyenDagger , Ngon E. NguyenDagger , Robert Stephenson§, William N. Pappano, Douglas R. Keene||, Suzanne M. Spong§, Daniel S. Greenspan, Paul R. Findell§, and M. Peter MarinkovichDagger **DaggerDagger

From the Dagger  Program in Epithelial Biology, Stanford University, Stanford, California 94305, § FibroGen, Inc., South San Francisco, California 94080,  Department of Pathology and Laboratory Medicine, University of Wisconsin, Madison, Wisconsin 53706, || Imaging Center, Shriners Hospital for Crippled Children, Portland, Oregon 97201, and ** Dermatology Service, Veterans Affairs Medical Center, Palo Alto, California 94304

Received for publication, October 16, 2002, and in revised form, December 5, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Laminin-5, a major adhesive ligand for epithelial cells, undergoes processing of its gamma 2 and alpha 3 chains. This study investigated the mechanism of laminin-5 processing by keratinocytes. BI-1 (BMP-1 isoenzyme inhibitor-1), a selective inhibitor of a small group of astacin-like metalloproteinases, which includes bone morphogenetic protein 1 (BMP-1), mammalian Tolloid (mTLD), mammalian Tolloid-like 1 (mTLL-1), and mammalian Tolloid-like 2 (mTLL-2), inhibited the processing of laminin-5 gamma 2 and alpha 3 chains in keratinocyte cultures in a dose-dependent manner. In a proteinase survey, all BMP-1 isoenzymes processed human laminin-5 gamma 2 and alpha 3 chains to 105- and 165-kDa fragments, respectively. In contrast, MT1-MMP and MMP-2 did not cleave the gamma 2 chain of human laminin-5 but processed the rat laminin gamma 2 chain to an 80-kDa fragment. An immunoblot and quantitative PCR survey of the BMP-1 isoenzymes revealed expression of mTLD in primary keratinocyte cultures but little or no expression of BMP-1, mTLL-1, or mTLL-2. mTLD was shown to cleave the gamma 2 chain at the same site as the previously identified BMP-1 cleavage site. In addition, mTLD/BMP-1 null mice were shown to have deficient laminin-5 processing. Together, these data identify laminin-5 as a substrate for mTLD, suggesting a role for laminin-5 processing by mTLD in the skin.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Proteolysis of the extracellular matrix is emerging as a key mechanism in processes such as wound healing and tumor metastasis (1, 2). Although most studies have investigated the role of serine proteases and matrix metalloproteases, members of the astacin and ADAM (a disintegrin and metalloprotease) families have also been implicated in this process (1, 2). Laminin-5, the major component of epithelial basement membranes, is a heterotrimeric protein consisting of alpha 3, beta 3, and gamma 2 subunits (3, 4). Laminin-5 undergoes extracellular proteolysis of the alpha 3 chain from a 200- to a 165-kDa form and of the gamma 2 chain from a 155- to a 105-kDa form (5). Through its interaction with alpha 3beta 1 (6, 7), alpha 6beta 4 (8), and alpha 2beta 1 integrins (9), laminin-5 supports epithelial cell adhesion (3, 10), and migration (11, 12).

Several proteases have been implicated in laminin-5 processing. Exogenous addition of matrix metalloprotease 2 (MMP-2)1 cleaved the gamma 2 subunit of rat laminin-5 (12). A subsequent study suggested that membrane type 1 matrix metalloprotease (MT1-MMP) may play a role in cleaving laminin-5 (13). Cleavage of laminin-5 by plasmin converted the alpha 3 chain into the 165-kDa form observed in human breast and rat epithelial cells and capable of nucleating hemidesmosomes (14). Bone morphogenetic protein 1 (BMP-1) has also been implicated in laminin-5 proteolysis. N-terminal sequencing of the 105-kDa gamma 2 chain obtained from human keratinocytes revealed a cleavage site that matched the minimal consensus sequence of this metalloprotease (15). In vitro studies demonstrated that BMP-1 cleaved the recombinant gamma 2 short arm at the predicted site and that the enzyme cleaved both the alpha 3 and gamma 2 chains of whole laminin-5 to generate characteristic 165- and 105-kDa fragments, respectively (15). Thus, of the proteases reported to cleave laminin-5, only BMP-1 was shown to process both chains, whereas plasmin was reported to process only the alpha 3 chain, and MMP-2 and/or MT1-MMP were reported to process only the gamma 2 chain of rat laminin-5.

BMP-1, first identified in osteogenic extracts of bone (16), is a metalloprotease of the astacin family (17). It has substantial homology with proteins involved in morphogenetic patterning such as Tolloid in Drosophila and Xolloid in Xenopus, and the mammalian enzyme may function both in patterning and in modifying components of the extracellular matrix (18). The first identified activity for BMP-1 was the cleavage of the C-terminal propeptide from procollagen types I-III in the process of collagen deposition in fibrillogenesis (19). Three additional mammalian enzymes highly homologous to BMP-1 have been reported: mammalian Tolloid, an alternatively spliced variant of the Bmp1 gene (mTLD) (20); mammalian Tolloid-like 1 (mTLL-1) (21) and mammalian Tolloid-like 2 (mTLL-2) (18). All of these BMP-1 isoenzymes share a similar domain structure comprising an N-terminal prodomain, an astacin-like metalloprotease domain, and several EGF (epidermal growth factor) and CUB domains (a widespread module found in developmentally regulated proteins), thought to be involved in mediating protein-protein interactions (17) (Fig. 1). mTLD, mTLL-1, and mTLL-2 also have additional C-terminal EGF and CUB domains not found in BMP-1 (18, 20, 21) (Fig. 1). The overall sequences of these three proteins have between 72 and 75% identity to one another, and identity is even higher in conserved regions such as the metalloprotease domain (18). In addition to procollagen C-proteinase activity, the BMP-1 isoenzymes have been reported to process prolysyl oxidase, probiglycan (22), and procollagen VII to their mature forms (23, 24), and to cleave Chordin (18).


View larger version (28K):
[in this window]
[in a new window]
 
Fig. 1.   Domain structure of BMP-1 isoenzymes. BMP-1 and mTLD are alternatively spliced products of the same gene. The positions of peptides against which antibodies used in this study were raised are indicated.

In the present study, we have utilized a novel inhibitor of the BMP-1 family to investigate processing of laminin-5 by the BMP-1 isoenzymes expressed in keratinocytes. We demonstrate that treatment of keratinocytes with this inhibitor significantly reduced the cleavage of both the alpha 3 and gamma 2 chains. A comparison of the enzymatic activities of the four BMP-1 isoenzymes on laminin-5 revealed that all forms are able to cleave both the alpha 3 and gamma 2 chains. However, only mTLD was present in significant quantities, at both the RNA and protein levels, in cultured keratinocytes under the conditions used in the study of laminin-5 cleavage. In addition, a defect of laminin-5 processing was demonstrated in skin lacking mTLD/BMP-1. Interestingly, neither MMP-2 nor MT1-MMP was able to cleave the gamma 2 chain of human laminin-5, although they cleaved the rat chain, most likely reflecting sequence differences between the two proteins. Together, these data suggest a novel role for mTLD in processing laminin-5 in keratinocytes and the skin.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Enzymes and Inhibitors-- Plasmin (United States Biological, Swampscott, MA or Calbiochem) and purified MMP-2 and MT1-MMP catalytic domains (Chemicon, Temecula, CA) were purchased from commercially available sources. BI-1 (a kind gift of FibroGen, Inc.), a selective hydroxamic acid inhibitor of BMP-1 and its isoenzymes, was dissolved in Me2SO.

A fluorogenic peptide containing a consensus BMP-1 cleavage site (49) was used to assess the inhibitory activity of BI-1 on BMP-1. In a similar assay, a fluorogenic peptide with the sequence Mca-P-L-G-L-Dpa(Dnp)-A-R-NH2 (where Mca is 7-methoxycoumarin-4-acetic acid and Dpa is dinitrophenylalanine) (excitation 360 nm, emission 465 nm; Bachem, catalog No. M-1895) was used to measure the inhibitory activity of BI-1 on MMP-1, MMP-2, and MMP-9. The latter enzymes were activated according to the manufacturer's instructions using p-aminophenylmercuric acetate. BMP-1, and activated MMP-1, -2, and -9 were incubated for 1 h at 37 °C in the presence of BI-1 and the appropriate fluorogenic peptide substrate (50 µM); the increase in fluorescence was used to determine initial rates. MMP-2 activity was also verified by examining its ability to digest chicken type I [3H]procollagen at 25 °C as described previously for rat type I collagen (25), except that products were detected by autoradiography instead of Coomassie staining. Type 1 [3H]procollagen was a kind gift from FibroGen, Inc. The effect of BI-1 on this reaction was examined. The activity of MT1-MMP and the effect of BI-1 on this enzyme were verified using pro-MMP-2 as a substrate and examining its conversion to the mature form. The digestions were analyzed by Western blot as below using antibody Ab-3 (Calbiochem) against MMP-2, which recognizes both the 66- and 72-kDa forms. All control reactions were run in buffer consisting of 50 mM Tris, pH 7.5, 150 mM NaCl, 5 mM CaCl2, 0.02% Brij 35.

Protein Analysis-- Proteins were separated by SDS-PAGE using NOVEX gels (Invitrogen) and analyzed by Western blot as described previously (26). Goat anti-rabbit or goat anti-mouse secondary antibodies were from Amersham Biosciences and were used according to the manufacturer's instructions. Blots were developed using a standard ECL kit (Amersham Biosciences) unless indicated otherwise.

Cell Culture-- For the cell-based laminin-5 cleavage assay, human primary keratinocytes (NHEK; BioWhittaker, or Cascade Biologics, Portland, OR) were grown in EpiLife medium (Cascade Biologics) containing 0.06 mM CaCl2. When testing BI-1 in cell-based assays, we supplemented the medium with extra CaCl2 to a final concentration of 0.3 mM. The gamma 2-deficient keratinocytes, LSV5 cells (27), transfected with plasmids encoding wild-type or gamma 2-pNC mutant gamma 2 chains (a kind gift from Dr. Gim Meneguzzi, Nice, France (28)) were cultured in a 1:1 mix of defined keratinocyte serum-free medium (Invitrogen) and Medium 154 (Cascade Biologics) (29). Rat bladder epithelial 804G cells were cultured as previously described (30). Primary dermal fibroblasts were obtained from BioWhittaker and grown in Dulbecco's modified Eagle's medium with 10% fetal bovine serum.

Recombinant BMP-1 Isoenzymes-- Purified BMP-1 and conditioned media from cell lines stably expressing FLAG-tagged mTLD, mTLL-1, and mTLL-2 were the kind gifts of FibroGen, Inc. The mTLD, mTLL-1, and mTLL-2 proteins were affinity purified over a FLAG-Sepharose column essentially as described (18). Concentrations of purified enzymes were assessed using BCA assays and by direct comparison of Coomassie-stained band intensity with protein standards of known concentration. The activity of the purified enzymes was assayed by measuring the cleavage of a fluorogenic peptide containing a consensus BMP-1 cleavage site (49). The ability of BMP-1, mTLD, and mTLL-1 to cleave type I [3H]procollagen was verified as described previously (18).

Antibodies-- A laminin-5 polyclonal rabbit antibody (pKal) was raised against laminin-5, purified from human keratinocyte conditioned media by antibody affinity chromatography as described previously (5). Monoclonal antibody 19562 against the gamma 2 chain of human laminin-5 was from Chemicon. The rabbit polyclonal antibody 1084 directed at domains IV and V of the mouse laminin gamma 2 chain (31), was the kind gift of Dr. Rupert Timpl, Martinsreid, Germany. The polyclonal antisera S.E.-85 and S.E.-144 directed against the alpha 3 and gamma 2 chains of laminin-5, respectively (32), were a kind gift from Dr. Gim Meneguzzi, Nice, France.

The following affinity purified rabbit polyclonal antibodies raised against peptides from BMP-1 isoenymes were kind gifts of FibroGen, Inc.: pAb 585 against the BMP-1 C terminus (33), pAb 586 against the mTLD C terminus (33), pAb 531 against the mTLL-1 catalytic domain, pAb 517 against the BMP-1 and mTLD catalytic domain, and pAb TLL2 against the mTLL-2 catalytic domain. The reactivity of each antibody against 0.25 µg of BMP-1, mTLD, mTLL-1, and mTLL-2 was assessed by Western blot. To test the presence of BMP-1 isoenzymes in keratinocyte medium, 90% confluent cultures of keratinocytes were washed three times to remove residual pituitary extract supplements and grown overnight in supplement-free medium (Keratinocyte SFM, Invitrogen). The conditioned media were collected, centrifuged at 4000 × g to remove cellular debris, and concentrated 100-200-fold using Centricon Plus 20 centrifugal concentrators (Millipore). Concentrated conditioned media derived from the culture of 1.5-2.5 × 106 cells were electrophoresed per lane alongside 0.2 µg of the purified BMP-1 isoenzymes as positive controls and analyzed by Western blot with the panel of anti-BMP-1 isoenzyme antibodies.

Immunoprecipitation of Unprocessed Laminin-5 and Enzyme Assays-- For immunoprecipitation, human primary keratinocytes were grown to 70% confluency in six 225-cm2 flasks, washed with Hanks' balanced salt solution (BioWhittaker) and Cys/Met-free keratinocyte growth medium (KGM; BioWhittaker), and then starved in the same medium for 30 min at 37 °C. Cells were labeled for 24 h in Cys/Met-free KGM supplemented with 0.1 mCi/ml EasyTag EXPRESS (PerkinElmer Life Sciences) protein labeling mix. After labeling, cells were lysed with ice-cold radioimmunoprecipitation assay buffer (5). Cell debris was removed by centrifugation at 14000 × g for 30 min at 4 °C. The supernatant was snap-frozen and stored at -80 °C until its use in immunoprecipitation.

For immunoprecipitation the supernatant was precleared with gelatin-Sepharose 4B (Amersham Biosciences) overnight at 4 °C using 100 µl of Sepharose/each ml of supernatant. Precleared supernatant was incubated overnight at 4 °C with protein G-Sepharose beads to which K140 had been preadsorbed. Beads were pelleted, washed, and resuspended in 2× digestion buffer (100 mM Tris, pH 7.5, 300 mM NaCl, 10 mM CaCl2, 0.04% Brij 35). For digestions, 15 µl of beads were digested in a final volume of 30 µl for 2 h at 37 °C.

Soluble, partially processed laminin-5 was purified from the conditioned media of LSV5 cells transfected with the wild-type gamma 2 chain, as described previously, using antibody affinity chromatography (5). 1 µg of purified protein was digested in a total volume of 20 µl of digestion buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 5 mM CaCl2) for 4 h at 37 °C.

To produce unprocessed rat laminin-5 for cleavage assays, 804G cells were seeded in 48-well plates at a density of 2 × 105 cells/well in the presence of 20 µM BI-1 inhibitor and grown for 16 h. Cells were removed using 20 mM NH4OH and the remaining matrix washed as described previously (34). Laminin-5 was digested in a total volume of 100 µl of digestion buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 5 mM CaCl2) containing proteases for 4 h at 37 °C. Following digestion, the matrix was washed twice with phosphate-buffered saline and solubilized as described previously (34). The processing state of laminin-5 was analyzed by Western blot using 1:1000 pKal with the signal detected using ECL Plus chemiluminescent reagent (Amersham Biosciences).

RNA Isolation and cDNA Synthesis-- Cytoplasmic RNA was isolated from cells using RNeasy reagent kit (Qiagen). RNA was subsequently treated with RNase-free DNase using an "on column" DNase digestion kit (Qiagen). RNA concentration was determined with RiboGreen (Molecular Probes). cDNA synthesis was performed on 200 ng of total RNA using OmniscriptTM reverse transcriptase (Qiagen), priming with oligo(dT) at a concentration of 1 µM. Placental RNA was obtained from Clontech.

Quantitative PCR-- Levels of gene expression were determined using a LightCycler instrument (Roche Applied Science) using the FastStart DNA Master SYBR Green (Roche Applied Science) with a final concentration of 4.1 mM MgCl2. The thermal cycling conditions began with polymerase activation at 94 °C for 6 min followed by 42 cycles at 95 °C for 15 s, 60 °C for 5 s, and 72 °C for 10 s. A standard curve comprising the gel-purified and PicoGreen (Molecular Probes)-quantitated amplicon from a previous PCR was run concurrently with each sample. Primers, used at a final concentration of 500 nM, are indicated in Table I. The equivalent cDNA made from 4 ng of total RNA was used in each PCR reaction.


                              
View this table:
[in this window]
[in a new window]
 
Table I
Primers used in quantitative PCR

Other Methods-- Indirect immunofluorescent (IDIF) microscopy and immunoelectron microscopy of skin samples were performed as described previously (35).

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Inhibition of Laminin-5 processing in Keratinocytes Using a BMP-1 Isoenzyme Inhibitor-- Extracellular processing of laminin-5 by keratinocytes was shown to be inhibited by ortho-phenanthroline, an inhibitor of metalloproteases, and sequence analysis of the cleavage site of the gamma 2 chain implicated BMP-1 in this activity (15). Moreover, BMP-1 cleaved both the alpha 3 and gamma 2 chains of radiolabeled, immunoprecipitated laminin-5 (15). In this study we have utilized BI-1, a hydroxamic acid-based selective inhibitor of BMP-1 isoenzymes, to investigate the role of these metalloproteases in laminin-5 processing. BI-1 has IC50 values of 6, 2, and 4 nM for BMP-1, mTLL-1, and mTLL-2 respectively compared with IC50 values of greater then 50 µM for MMP-2 and MMP9.2

Under the culture medium calcium concentrations used in this study, keratinocytes produced a mixture of unprocessed and processed forms of both the alpha 3 and gamma 2 chains of laminin-5 in the extracellular matrix (Fig. 2A, i). When cells were seeded and grown in the presence of increasing concentrations of BI-1 for 72 h, the appearance of the unprocessed 200-kDa alpha 3 and 155-kDa gamma 2 bands indicated that the inhibition was dose-dependent (Fig. 2A, i). The kinetics of cleavage differed for the two chains. Cleavage of the gamma 2 chain was 85% inhibited at 0.5 µM BI-1 (Fig. 2A, iii). In contrast, processing of the alpha 3 chain appeared more complex. In the absence of the inhibitor, three bands were apparent: the 200-kDa unprocessed form, the 165-kDa form processed at the C-terminal end of the chain, and a 145-kDa form, which had undergone additional processing in domain IIIa of the N-terminal region (Fig. 2A, ii) (5, 15). These forms comprise 14, 52, and 34%, respectively, of the total alpha 3 (Fig. 2B). The addition of BI-1 inhibits both of these cleavage events, with the 145-kDa band reduced to 9% of the total at 5 µM BI-1, whereas the 165-kDa band still comprised 28% of the total alpha 3 at 50 µM BI-1 (Fig. 2B). This may indicate that the cleavage site in the G-domain, which generates the 165-kDa fragment, is particularly labile and sensitive to proteolysis.


View larger version (39K):
[in this window]
[in a new window]
 
Fig. 2.   BI-1 specifically inhibits laminin-5 processing in human keratinocytes. A, keratinocytes were incubated for 72 h with increasing concentrations of BI-1. Extracellular matrix was harvested from cells and probed with the following pAbs: pKal to detect laminin-5 (i), SE85 to detect the alpha 3 chain (ii), and SE144 to detect the gamma 2 chain (iii). B, SE85 and SE144 blots were analyzed by densitometry. i, black-diamond , unprocessed alpha 3 200-kDa band; black-square, processed alpha 3 165-kDa band; black-triangle, processed alpha 3 145-kDa band. ii, black-diamond , processed gamma 2 105-kDa band.

Laminin-5 alpha 3 and gamma 2 Chains Are Substrates for all BMP-1 Isoenzymes-- BMP-1 has been reported to cleave both the alpha 3 and gamma 2 chains of radiolabeled human laminin-5 immunoprecipitated from keratinocyte cell lysates (15). To determine whether other BMP-1 isoenzymes were also capable of catalyzing this reaction, we tested the ability of the panel of BMP-1 isoenzymes to cleave unprocessed laminin-5. Purified recombinant BMP-1, mTLD, mTLL-1, and mTLL-2 used in the digestions were present as single bands on a Coomassie-stained SDS-polyacrylamide gel with molecular weights corresponding to those of the mature proteins from which proregions had been proteolytically removed (18) (Fig. 3A). Their proteolytic activity was assayed using a fluorogenic peptide containing a consensus BMP-1 cleavage sequence, and all enzymes were found to have similar activity (Fig. 3A). In addition, the ability of BMP-1, mTLD, and mTLL-1 to cleave type I procollagen as reported previously (18) was confirmed (data not shown). mTLL-2 also cleaved type I procollagen at a low efficacy, similar to the efficiencies of mTLD and mTLL-1 (data not shown).


View larger version (44K):
[in this window]
[in a new window]
 
Fig. 3.   BMP-1 isoenzymes digest alpha 3 and gamma 2 chains of laminin-5. A, BMP-1 isoenzymes were purified as described previously (18). The activity of 0.1 µg of protein was determined using a fluorogenic peptide containing a consensus BMP-1 cleavage site and expressed as % cleavage/h ± S.D. B, radiolabeled, immunoprecipitated human laminin-5 was incubated with 100 nM BMP-1 isoenzymes for 2 h in the presence and absence of 10 µM BI-1. Bands were detected by autoradiography. C, radiolabeled human laminin-5 was immunoprecipitated from LSV5 cells containing either the wild-type gamma 2 chain (g2) or the BMP-1 site mutant gamma 2 chain (pNC). Wild-type and mutant proteins were digested for 2 h with 100 nM BMP-1 isoenzymes, and the cleaved gamma 2 bands (105 kDa) were detected by autoradiography.

Radiolabeled, unprocessed intracellular human laminin-5 was immunoprecipitated from keratinocytes and used as a substrate for digestion. Under the conditions of the assay, unprocessed laminin-5 was completely stable in the absence of added enzyme (Fig. 3B). Digestion of unprocessed laminin-5 with each BMP-1 isoenzyme at 100 nM resulted in the appearance of the 165-kDa processed alpha 3 chain and the 105-kDa processed gamma 2 band. No smaller molecular weight gamma 2 chain fragments were observed. The laminin-5 cleavage activities using 100 nM BMP-1, mTLD, mTLL-1, and mTLL-2 were abolished in the presence of 10 µM BI-1, and only the unprocessed alpha 3 and gamma 2 forms were observed.

mTLD, mTLL-1, and mTLL-2 Cleave the gamma 2 Chain of Laminin-5 at the BMP-1 Site-- BMP-1 has been shown to cleave the human laminin-5 gamma 2 chain at a site identical to that which generates the 105-kDa fragment found physiologically (15). To determine whether other BMP-1 isoenzymes also cleaved this chain at an identical site, we used a mutant gamma 2 chain, gamma 2-pNC, in which the four-amino acid BMP-1 site (YSGD) was deleted (28). This construct was stably transfected into keratinocytes lacking the gamma 2 chain (LSV5) (27) and was used to produce laminin-5 containing the mutant gamma 2 chain. Likewise, wild-type gamma 2 was generated by transfection of LSV5 cells with a plasmid encoding the wild-type gamma 2 chain. Mutant and wild-type laminin-5 were radiolabeled and immunoprecipitated from these cells and used as substrates for digestion. All BMP-1 isoenzymes cleaved the gamma 2 chain of the wild-type laminin-5, whereas none of the enzymes cleaved the gamma 2 chain of the mutant laminin-5, indicating that all BMP-1 isoenzymes cleave the gamma 2 chain at the established BMP-1 site (Fig. 3C).

Cleavage of Laminin-5 by MMP-2, MT1-MMP, and Plasmin-- In addition to BMP-1, the metalloproteases MMP-2 and MT1-MMP have been reported to cleave the gamma 2 chain of laminin-5 (12, 13). To clarify the role of these enzymes in laminin-5 processing and to compare their activity with that of BMP-1, we studied their cleavage activity on both human and rat laminin-5. To verify the activity of MT1-MMP and the specificity of BI-1, we digested pro-MMP-2 to its active form with MT1-MMP in the presence and absence of the inhibitor. Likewise, MMP-2 activity was tested using chicken type I procollagen as a substrate, because MMP-2 had previously been shown to cleave rat type I collagen (25). Neither MMP-2 cleavage by MT1-MMP nor procollagen cleavage by MMP-2 was inhibited by 10 µM BI-1 (Fig. 4A). To directly compare the abilities of MMP-2 and MT1-MMP to cleave laminin-5 with those of the BMP-1 isoenzymes, we tested the activities of these proteases by digesting labeled immunoprecipitated human laminin-5 as described above. Surprisingly, neither MMP-2 nor MT1-MMP cleaved the gamma 2 chain to either the 105-kDa or 80-kDa forms, even at enzyme concentrations as high as 300 nM (Fig. 4B). However, both enzymes cleaved the alpha 3 chain to the 165-kDa form, and these processing events were not inhibited by 10 µM BI-1 (Fig. 4B).


View larger version (63K):
[in this window]
[in a new window]
 
Fig. 4.   MMP-2 and MT1-MMP digest rat but not human 5 gamma 2 chain. A, the activity of MMP-2 was verified using a 24-h digestion of chicken type I [3H]procollagen as a substrate, and the activity of MT1-MMP was verified using pro-MMP-2 as a substrate. B, radiolabeled, immunoprecipitated human laminin-5 was digested for 2 h with MT1-MMP, MMP-2, and plasmin in the presence and absence of BI-1. C, 1 µg of purified, partially processed human laminin-5 was digested with increasing concentrations of MT1-MMP for 16 h. Products were detected by Western blot using monoclonal antibody 19562 against the human laminin-5 gamma 2 chain (Chemicon). D, rat bladder epithelial 804G cells were grown in the absence or presence of 20 µM BI-1 for 16 h. Cells were removed, and matrix laminin-5 was digested with MMP-2, MT1-MMP, or BMP-1 for 4 h. The matrix was solubilized and laminin-5 detected by Western blot with pKal.

Recently, it was reported that digestion of soluble human laminin-5 gamma 2 chain with MT1-MMP generated several bands smaller than 105 kDa (36). In our studies with immunoprecipitated laminin-5, the protein used in enzyme digestion reactions is complexed to Sepharose beads. We therefore examined the ability of MT1-MMP to digest soluble laminin-5. No cleavage of the gamma 2 chain was seen at molar ratios of MT1-MMP to laminin-5 up to 3:1 (Fig. 4C), confirming our results obtained with the immunoprecipitated laminin-5. We were also unable to demonstrate MMP-2- or MT1-MMP-mediated cleavage of laminin-5 deposited upon tissue culture plastic by human keratinocytes, a substrate that is cleaved by BMP-1 isoenzymes (data not shown).

The lack of a clear 80-kDa (gamma 2p') laminin-5 band in any of our MMP-2 and MT1-MMP digestions is contrary to the findings of previous studies but may be explained by the use of human instead of rat laminin-5, as the two share no identity at the MMP-2 cleavage site (residues 582-589 in rat and 601-608 in human). We therefore examined rat laminin-5 from the extracellular matrix of rat bladder epithelial 804G cells, which contains a laminin gamma 2 chain typically processed to a mixture of 105 (gamma 2p)- and 80 (gamma 2p')-kDa fragments. When 804G cells were cultured in the presence of BI-1, only the processed 80-kDa gamma 2 band was detected; the addition of MMP-2 or MT1-MMP to this material resulted in the full conversion of unprocessed gamma 2 to the 80-kDa band. No gamma 2p band at 105 kDa was detected (Fig 4D). The addition of BMP-1 generated the gamma 2p but not the gamma 2p' fragments, as observed with the human substrate. These results suggest that both BMP-1 isoenzymes and MMPs are active in processing laminin-5 in this rat cell line, and that MMP-2 and MT1-MMP directly convert the 155-kDa gamma 2 chain to the 80-kDa gamma 2p' form without cleavage to an intermediate form.

The serine protease, plasmin, was reported to cleave the alpha 3 chain of laminin-5 (14). The addition of 100 nM plasmin cleaved the alpha 3 chain of laminin-5 to the characteristic 165-kDa band (Fig. 4B). The size of this band is indistinguishable from that seen for laminin-5 processed by keratinocytes or for laminin-5 digested by BMP-1, mTLL-1, or mTLL-2. Plasmin also appeared to cleave the gamma 2 chain to the 105-kDa form. The addition of 10 µM BI-1 did not inhibit the digestion activity of plasmin on either the alpha 3 or gamma 2 chains (Fig. 4B).

The Major Secreted BMP-1 Isoenzyme in Cultured Human Keratinocytes Is mTLD-- To identify which BMP-1 isoenzyme is secreted by human keratinocytes, we analyzed keratinocyte conditioned media by Western blot. Keratinocytes have been reported to secrete predominantly mTLD in its proenzyme form in response to TGFbeta 1 (33). However, neither mTLL-1 nor mTLL-2 was examined in this previous report. To study all BMP-1 isoenzymes, we initially determined the reactivities of a panel of antibodies with BMP-1, mTLD, mTLL-1, and mTLL-2. pAb 517, raised against the catalytic domain of BMP1/mTLD, cross-reacted strongly with all four isoenzymes (Fig. 5A, lanes 6-9). pAb 585, raised against the C terminus of BMP-1, recognized only this enzyme, whereas pAb 586, raised against the C terminus of mTLD, recognized this isoenzyme and also mTLL-2. pAb 531, raised against the catalytic domain of mTLL-1, was specific for mTLL-1, and pAb Tll-2, raised against the analogous sequence in the catalytic domain of mTLL-2 to pAb 531, recognized both mTll-2 and mTll-1 (Fig. 5B). Thus BMP-1, mTLD, mTLL-1, and mTLL-2 each have a unique pattern of reactivities with this panel of antibodies.


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 5.   mTLD is the major BMP-1 isoenzyme present in conditioned keratinocyte media. A, lanes 1-6, conditioned keratinocyte medium was concentrated as described under "Experimental Procedures" and immunoblotted with: lane 1, pAb 517; lane 2, pAb 585; lane 3, pAb 586; lane 4, pAb 531; lane 5, pAb mTll-2. Lanes 6-9, 0.25 µg of BMP-1, mTLD, mTLL-1, and mTLL-2, respectively, were immunoblotted with pAb 517. B, reactivity of BMP-1, mTLD, mTLL-1, and mTLL-2 with a panel of antibodies against BMP-1 isoenzymes.

When concentrated conditioned keratinocyte medium was analyzed using these antibodies, a doublet at ~130 and 140 kDa was detected with pAb 517 and pAb 586 antibodies only (Fig. 5A, lanes 1 and 3). No bands were detected with any of the other antibodies that were not also present in the serum only control (Fig. 5A, lanes 2, 4, and 5). From this pattern of reactivity, we conclude that mTLD is the major BMP-1 isoenzyme found in keratinocyte conditioned media. The molecular masses of the two bands are in the range of the proenzyme, predicted from sequence data to be 143 kDa, and the mature form of mTLD, reported to be 130 kDa (18). A minor 100-kDa band detected with pAb 517 and pAb 586 is likely a degradation product of mTLD.

Expression of RNA levels for the BMP-1 isoenzymes in primary keratinocytes was also assessed using quantitative PCR, with placental and fibroblastic RNA as positive controls for BMP-1 and mTLD. A suitable positive control RNA could not be found for mTll-2, but primers were validated using a plasmid containing the mTLL-2 cDNA. In agreement with the detection of only mTLD in conditioned keratinocyte media, this isoenzyme was the most abundant form in keratinocytes, expressed at levels approximately two orders of magnitude greater than BMP-1 and mTLL-1 (Table II). Human dermal fibroblasts also expressed significant levels of mTLD. No mTLL-2 was detected in any of the samples analyzed.


                              
View this table:
[in this window]
[in a new window]
 
Table II
RNA expression levels of BMP-1 isoenzymes
Number of transcripts of different BMP-1 isoenzymes/ng of total RNA was determined by quantitative PCR using primers listed in Table I. The following human cell lines and tissues were examined: NHEK, human primary keratinocytes; NHDF, human primary fibroblasts. Numbers in italics indicate samples that were either below the standard curve or near the water blank.

mTLD/BMP-1-deficient Skin Shows Defective Laminin-5 Processing-- Given that all BMP-1 isoenzymes are capable of cleaving both the alpha 3 and gamma 2 chains of laminin-5, the presence of mTLD in keratinocyte conditioned media suggests that mTLD may be the enzyme responsible for cleaving laminin-5 in skin. To further evaluate this possibility, we examined mTLD/BMP-1-deficient skin prepared from embryos homozygous null for the Bmp1 gene (37), which encodes both proteases, using pAb 1084 directed at domains IV and V of the laminin gamma 2 chain. This antibody recognizes only those laminin-5 molecules that contain an unprocessed gamma 2 chain (38). Increased unprocessed laminin gamma 2 chain was noted at the dermal-epidermal junction in mTLD/BMP-1-deficient skin compared with wild-type skin in E18 mouse embryos by IDIF microscopy (Fig. 6, A and C). In contrast, expression of total laminin-5, detected by the pKal pAb, was similar in both samples (Fig. 6, B and D). As a next step, we examined the localization of laminin-5 in mTLD/BMP-1-deficient and wild-type skin using immuno-electron microscopy. As with IDIF studies, increased unprocessed extracellular laminin gamma 2 chain was noted in mTLD/BMP-1-deficient skin (Fig. 6, F and G) relative to wild-type skin (Fig. 6E). Extracellular unprocessed laminin-5 appeared to localize predominantly to the lamina densa. Although blister formation was not clinically apparent in mTLD/BMP-1-deficient mouse skin, at the ultrastructural level the lamina densa was often not well opposed to overlying hemidesmosomes, and hemidesmosomes were often rudimentary in appearance in mTLD/BMP-1-deficient skin (e.g. Fig. 6F). When complete separation of the epidermis and dermis was noted in deficient skin, it appeared to occur in the plane of the lamina lucida with unprocessed laminin gamma 2 chain localizing to the dermal side of the skin separation (e.g. Fig. 6G).


View larger version (66K):
[in this window]
[in a new window]
 
Fig. 6.   mTLD/BMP-1-deficient skin shows defective laminin-5 processing. mTLD/BMP-1-deficient skin from E18 mouse embryo (A, B, F, and G) or wild-type E18 littermate skin (C, D, and E) were analyzed by IDIF microscopy (A-D) or by immunoelectron microscopy (E-G) using pAb 1084, recognizing unprocessed laminin gamma 2 chain (A, C, E, F, and G) or the pAb pKal, recognizing total laminin-5 (B and D). Note the increased amounts of unprocessed laminin-5 in mTLD/BMP-1-deficient skin samples. LD, lamina densa. Arrows indicate hemidesmosomes. Bars in A-D, 50 µm; bars in E-G, 200 nm.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The selective inhibitor BI-1 has facilitated the study of laminin-5 processing in vitro. BI-1, at the concentrations used, inhibits the BMP-1 isoenzymes but does not inhibit other metalloproteases such as MMP-2 and MT1-MMP, and thus it functions as a tool for distinguishing the effect of these enzymes in cellular processes. In vitro digestion assays of unprocessed laminin-5 with BMP-1 isoenzymes, analysis of conditioned keratinocyte media with a panel of antibodies against these isoenzymes, and quantitative PCR studies together suggest that mTLD mediates laminin-5 cleavage in primary keratinocytes.

Interestingly, the alpha 3 and gamma 2 chains are not equivalent in terms of sensitivity to proteolysis. Processing of the gamma 2 chain was inhibited at substantially lower concentrations of BI-1 than either of the alpha 3 chain cleavages. Similarly, in cell culture there is a lag in gamma 2 processing relative to alpha 3 processing (5, 15). The kinetics of this cleavage may reflect a greater accessibility of the protease to the alpha 3 chain cleavage site than to the gamma 2 cleavage site or the fact that cleavage of the alpha 3 chain cooperatively enhances gamma 2 chain cleavage. The physiological significance of these kinetics may be linked to the differing roles played by the individual chains in influencing cellular processes such as adhesion, migration, and matrix assembly.

BMP-1 isoenzymes have been shown to be generally similar in their substrate specificities, with all enzymes capable of processing pro-lysyl oxidase (18) and procollagen (16) (and this report) to their mature forms. It is probable that these similarities reflect the need for redundancy in the biological functions of the BMP-1 isoenzymes. This was demonstrated previously in Bmp1 knockout mice in which deficiency of BMP-1 and mTLD did not prevent processing of type I and type VII procollagens, indicating the involvement of several isoforms in these activities (24, 37). The similarity of the BMP-1 isoenzyme activities is likewise indicated by the fact that all enzymes are processed at the gamma 2-chain at the same established BMP-1 cleavage site.

The presence of mTLD, and the apparent absence of the other BMP-1 isoforms in keratinocyte media by Western blot analysis, as well as the predominant expression of mTLD in primary keratinocytes and fibroblasts by quantitative PCR analysis all suggest that mTLD is likely active in cleaving laminin-5 in vivo. TGFbeta 1 stimulation was not required to detect the mTLD bands in keratinocyte media in this study despite a previous report that the unprocessed form of mTLD is detected only in response to TGFbeta 1 (33). The differing results could reflect the 3-5-fold greater amount of conditioned media loaded in the current study than in the previous report (33), as no specific bands were detected when less than this amount of media was analyzed.

BMP-1 and laminin-5 were previously shown to co-localize at the dermal-epidermal junction of fetal calf skin (15). The polyclonal antibody used in that study was raised against BMP-1 but is reactive against both BMP-1 and mTLD.3 Furthermore, BMP-1/mTLD localized to basal keratinocytes in normal human skin, whereas mTLL-1 expression was absent in basal keratinocytes (24). These results are consistent with a role for mTLD in the dermal-epidermal basement membrane and, coupled with our findings of defective laminin-5 processing in mTLD/BMP-1-deficient mice, support the hypothesis that mTLD is involved with the processing of the laminin-5 gamma 2 and alpha 3 chains in vivo.

Previous studies have shown that MMP-2 (12) and MT1-MMP (13) each cleaved the laminin-5 gamma 2 chain, in apparent contradiction to our study. However, these previous studies used rat laminin-5, whereas our study examined human laminin-5. The sequence of the rat gamma 2 chain at the MMP-2 cleavage site (residues 582-589) (12) has very low identity with the corresponding region of the human protein (residues 601-608), which likely explains the observed lack of cleavage of human laminin gamma 2 chain by MMP-2 in our experiments. It is quite possible that MMP-2 and MT1-MMP cleave the same unconserved site on the rat laminin gamma 2 chain, because each enzyme yields a similar 80-kDa product; however, the sequence of the MT1-MMP cleavage site has not been reported. Although MMP-2 and MT1-MMP cleaved rat laminin gamma 2 chain to the 80-kDa fragment, neither enzyme, even at concentrations as high as 300 nM, could convert laminin-5 gamma 2 chain to the 105-kDa fragment (12, 13), which is the only processed product of the laminin gamma 2 chain found in human tissues (5).

MMP-2 and MT1-MMP are known to be expressed in human keratinocytes (39-42). However, laminin-5 processing in keratinocyte cultures was completely inhibited by BI-1, which we have shown to have no effect on MMP-2 or MT1-MMP activity. These findings, coupled with the observation that the sequence of the human gamma 2 chain in vivo cleavage site exactly matches that of the BMP-1-cleaved gamma 2 chain in vitro (15), suggest that neither MMP-2 nor MT1-MMP is likely to play a role in processing the human laminin gamma 2 chain. Interestingly, the addition of BI-1 to rat 804G cells inhibited the generation of the gamma 2p but not gamma 2p' fragments, which suggests that one of the BMP-1 isoenzymes may be cleaving rat laminin-5 in addition to MMP-2 or MT1-MMP in these cells. The relative contribution of each of these enzymes to laminin-5 cleavage in the rat model is an area deserving of further investigation.

Although neither MMP-2 nor MT1-MMP cleaved the human laminin gamma 2 chain, both enzymes, as well as all other proteases examined in this and other reports, were able to cleave the alpha 3 chain to a fragment indistinguishable in size from the 165-kDa product observed in the extracellular matrix of cultured keratinocytes. This panel included a serine protease, plasmin, and members of the astacin and matrix metalloprotease families. This suggests that the alpha 3 cleavage site lies on a portion of the chain that is highly sensitive to proteolytic attack, consistent with electron micrograph data that places the cleavage site in an accessible spacer region between globular domains G3 and G4 (43). Recently, the C-terminal peptide released after cleavage of the 200-kDa alpha 3 chain was isolated from the conditioned medium of human keratinocytes (44). The N-terminal sequence of this fragment suggested that a member of the MMP, astacin, or ADAM families could act as the processing enzyme of this chain (44). In a separate report, partial sequencing of two fragments of 35 and 37 kDa released by cleavage of the alpha 3 chain indicated that cleavage occurred in the region between the G3 and G4 domains (45). Although MMP-2 and MT1-MMP do cleave the alpha 3 chain in our in vitro assays, this may not be physiologically relevant, as these enzymes are not inhibited by BI-1, which prevents most laminin-5 processing when added to keratinocyte cultures. This observation does not preclude a role for these enzymes in the upstream activation of another protease involved in cleavage of the alpha 3 chain. Our results hint at a heretofore unsuspected complexity of laminin-5 processing in which different enzymes may cleave the alpha 3 and gamma 2 chains and in which alpha 3 chain processing itself may involve more than one protease.

The involvement of proteases of the MMP family and plasmin in modifying the extracellular matrix in the process of carcinoma invasion is well established (1, 2). It has been suggested that members of the astacin family may also play a role in these processes (1). Proteolytic modification of laminin-5 structure has been shown to be an important process underlying keratinocyte migration, wound healing, and tumor invasion. In particular, increased expression of laminin-5 is often observed at the margins of squamous cell carcinoma tumors (46-48), and thus processing of such laminin-5 by BMP-1 isoenzymes may be a critical step in invasion. Therefore, specific inhibitors of BMP-1 isoenzymes, such as BI-1, may prove to be invaluable in the study of laminin-5 processing in squamous cell carcinoma invasion.

    ACKNOWLEDGEMENTS

We thank Dr. Edgar Fincher (Stanford University) and Drs. Mitchell Brenner and George Martin (FibroGen, Inc.) for helpful discussions. We thank Sara Tufa (Portland Shriners Hospital) for excellent technical assistance with electron microscopy and Dr. Ben Ho (Fibrogen) for assistance with inhibitor production.

    FOOTNOTES

* This work was funded through the Office of Research, Palo Alto Veterans Affairs Medical Center, National Institutes of Health Grants P01-AR44012-01 and R01-AR47223-01 (to M. P. M.), and a grant from the Skin Cancer Foundation.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Dagger To whom correspondence should be addressed: Program in Epithelial Biology, 269 Campus Dr., Rm. 2145, Stanford, CA 94305. Tel.: 650-498-5425; Fax: 650-723-8762; E-mail: mpm@stanford.edu.

Published, JBC Papers in Press, December 7, 2002, DOI 10.1074/jbc.M210588200

2 M. Brenner, personal communication.

3 D. S. Greenspan, unpublished data.

    ABBREVIATIONS

The abbreviations used are: MMP, matrix metalloprotease; BMP, bone morphogenetic protein; mTLD, mammalian Tolloid; mTLL-1 and -2, mammalian Tolloid-like 1 and 2; MT1-MMP, membrane type 1 matrix metalloprotease; IDIF, indirect immunofluorescence; pAb, polyclonal antibody(s).

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Murphy, G., and Gavrilovic, J. (1999) Curr. Opin. Cell Biol. 11, 614-621[CrossRef][Medline] [Order article via Infotrieve]
2. Quaranta, V. (2000) J. Cell Biol. 149, 1167-1170[Abstract/Free Full Text]
3. Rousselle, P., Lunstrum, G. P., Keene, D. R., and Burgeson, R. E. (1991) J. Cell Biol. 567-576
4. Marinkovich, M. P., Verrando, P., Keene, D. R., Meneguzzi, G., Lunstrum, G. P., Ortonne, J. P., and Burgeson, R. E. (1993) Lab. Invest. 69, 295-299[Medline] [Order article via Infotrieve]
5. Marinkovich, M. P., Lunstrum, G. P., and Burgeson, R. E. (1992) J. Biol. Chem. 267, 17900-17906[Abstract/Free Full Text]
6. Carter, W. G., Ryan, M. C., and Gahr, P. J. (1991) Cell 65, 559-610
7. Mizushima, H., Takamura, H., Miyagi, Y., Kikkawa, Y., Yamanaka, N., Yasumitsu, H., Misugi, K., and Miyazaki, K. (1997) Cell Growth Differ. 8, 979-987[Abstract]
8. Sonnenberg, A., de Melker, A. A., Martinez de Velasco, A. M., Janssen, H., Calafat, J., and Niessen, C. M. (1993) J. Cell Sci. 106, 1083-1102[Abstract/Free Full Text]
9. Decline, F., and Rousselle, P. (2001) J. Cell Sci. 114, 811-823[Abstract/Free Full Text]
10. Baker, S. E., Hopkinson, S. B., Fitchmun, M., Andreason, G. L., Frasier, F., Plopper, G., Quaranta, V., and Jones, J. C. R. (1996) J. Cell Sci. 109, 2509-2520[Abstract/Free Full Text]
11. Miyazaki, K., Kikkawa, Y., Nakamura, A., Yasumitsu, H., and Umeda, M. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 11767-11771[Abstract]
12. Giannelli, G., Falk-Marzillier, J., Schiraldi, O., Stetler-Stevenson, W. G., and Quaranta, V. (1997) Science 277, 225-228[Abstract/Free Full Text]
13. Koshikawa, N., Giannelli, G., Cirulli, V., Miyazaki, K., and Quaranta, V. (2000) J. Cell Biol. 148, 615-624[Abstract/Free Full Text]
14. Goldfinger, L. E., Stack, M. S., and Jones, J. C. (1998) J. Cell Biol. 141, 255-265[Abstract/Free Full Text]
15. Amano, S., Scott, I. C., Takahara, K., Koch, M., Champliaud, M. F., Gerecke, D. R., Keene, D. R., Hudson, D. L., Nishiyama, T., Lee, S., Greenspan, D. S., and Burgeson, R. E. (2000) J. Biol. Chem. 275, 22728-22735[Abstract/Free Full Text]
16. Wozney, J. M., Rosen, V., Celeste, A. J., Mitsock, L. M., Whitters, M. J., Kriz, R. W., Hewick, R. M., and Wang, E. A. (1988) Science 242, 1528-1534[Medline] [Order article via Infotrieve]
17. Bond, J. S., and Beynon, R. J. (1995) Protein Sci. 4, 1247-1261[Abstract/Free Full Text]
18. Scott, I. C., Blitz, I. L., Pappano, W. N., Imamura, Y., Clark, T. G., Steiglitz, B. M., Thomas, C. L., Maas, S. A., Takahara, K., Cho, K. W., and Greenspan, D. S. (1999) Dev. Biol. 213, 283-300[CrossRef][Medline] [Order article via Infotrieve]
19. Kessler, E., Takahara, K., Biniaminov, L., Brusel, M., and Greenspan, D. S. (1996) Science 271, 360-362[Abstract]
20. Takahara, K., Lyons, G. E., and Greenspan, D. S. (1994) J. Biol. Chem. 269, 32572-32578[Abstract/Free Full Text]
21. Takahara, K., Brevard, R., Hoffman, G. G., Suzuki, N., and Greenspan, D. S. (1996) Genomics 34, 157-165[CrossRef][Medline] [Order article via Infotrieve]
22. Scott, I. C., Imamura, Y., Pappano, W. N., Troedel, J. M., Recklies, A. D., Roughley, P. J., and Greenspan, D. S. (2000) J. Biol. Chem. 275, 30504-30511[Abstract/Free Full Text]
23. Uzel, M. I., Scott, I. C., Babakhanlou-Chase, H., Palamakumbura, A. H., Pappano, W. N., Hong, H. H., Greenspan, D. S., and Trackman, P. C. (2001) J. Biol. Chem. 276, 22537-22543[Abstract/Free Full Text]
24. Rattenholl, A., Pappano, W. N., Koch, M., Keene, D. R., Kadler, K. E., Sasaki, T., Timpl, R., Burgeson, R. E., Greenspan, D. S., and Bruckner-Tuderman, L. (2002) J. Biol. Chem. 277, 26372-26378[Abstract/Free Full Text]
25. Aimes, R. T., and Quigley, J. P. (1995) J. Biol. Chem. 270, 5872-5876[Abstract/Free Full Text]
26. Lunstrum, G. P., Sakai, L. Y., Keene, D. R., Morris, N. P., and Burgeson, R. E. (1986) J. Biol. Chem. 261, 9042-9048[Abstract/Free Full Text]
27. Miquel, C., Gagnoux-Palacios, L., Durand-Clement, M., Marinkovich, P., Ortonne, J. P., and Meneguzzi, G. (1996) Exp. Cell Res. 224, 279-290[CrossRef][Medline] [Order article via Infotrieve]
28. Gagnoux-Palacios, L., Allegra, M., Spirito, F., Pommeret, O., Romero, C., Ortonne, J. P., and Meneguzzi, G. (2001) J. Cell Biol. 153, 835-850[Abstract/Free Full Text]
29. Normand, J., and Karasek, M. A. (1995) In Vitro Cell. Dev. Biol. Anim. 31, 447-455[Medline] [Order article via Infotrieve]
30. Riddelle, K. S., Green, K. J., and Jones, J. C. (1991) J. Cell Biol. 112, 159-168[Abstract]
31. Brakebusch, C., Grose, R., Quondamatteo, F., Ramirez, A., Jorcano, J. L., Pirro, A., Svensson, M., Herken, R., Sasaki, T., Timpl, R., Werner, S., and Fassler, R. (2000) EMBO J. 19, 3990-4003[Abstract/Free Full Text]
32. Aberdam, D., Aguzzi, A., Baudoin, C., Galliano, M. F., Ortonne, J. P., and Meneguzzi, G. (1994) Cell Adhes. Commun. 2, 115-129[Medline] [Order article via Infotrieve]
33. Lee, S., Solow-Cordero, D. E., Kessler, E., Takahara, K., and Greenspan, D. S. (1997) J. Biol. Chem. 272, 19059-19066[Abstract/Free Full Text]
34. Langhofer, M., Hopkinson, S. B., and Jones, J. C. (1993) J. Cell Sci. 105, 753-764[Abstract/Free Full Text]
35. Keene, D. R., Marinkovich, M. P., and Sakai, L. Y. (1997) Microsc. Res. Tech. 38, 394-406[CrossRef][Medline] [Order article via Infotrieve]
36. Gilles, C., Polette, M., Coraux, C., Tournier, J. M., Meneguzzi, G., Munaut, C., Volders, L., Rousselle, P., Birembaut, P., and Foidart, J. M. (2001) J. Cell Sci. 114, 2967-2976[Medline] [Order article via Infotrieve]
37. Suzuki, N., Labosky, P. A., Furuta, Y., Hargett, L., Dunn, R., Fogo, A. B., Takahara, K., Peters, D. M., Greenspan, D. S., and Hogan, B. L. (1996) Development 122, 3587-3595[Abstract/Free Full Text]
38. Sasaki, T., Gohring, W., Mann, K., Brakebusch, C., Yamada, Y., Fassler, R., and Timpl, R. (2001) J. Mol. Biol. 314, 751-763[CrossRef][Medline] [Order article via Infotrieve]
39. Baumann, P., Zigrino, P., Mauch, C., Breitkreutz, D., and Nischt, R. (2000) Br. J. Cancer 83, 1387-1393[CrossRef][Medline] [Order article via Infotrieve]
40. Salo, T., Lyons, J. G., Rahemtulla, F., Birkedal-Hansen, H., and Larjava, H. (1991) J. Biol. Chem. 266, 11436-11441[Abstract/Free Full Text]
41. Larjava, H., Lyons, J. G., Salo, T., Makela, M., Koivisto, L., Birkedal-Hansen, H., Akiyama, S. K., Yamada, K. M., and Heino, J. (1993) J. Cell. Physiol. 157, 190-200[Medline] [Order article via Infotrieve]
42. Uitto, V. J., Firth, J. D., Nip, L., and Golub, L. M. (1994) Ann. N. Y. Acad. Sci. 732, 140-151[Abstract]
43. Beck, K., Hunter, I., and Engel, J. (1990) FASEB J. 4, 148-160[Abstract/Free Full Text]
44. Tsubota, Y., Mizushima, H., Hirosaki, T., Higashi, S., Yasumitsu, H., and Miyazaki, K. (2000) Biochem. Biophys. Res. Commun. 278, 614-620[CrossRef][Medline] [Order article via Infotrieve]
45. Nguyen, B. P., Gil, S. G., and Carter, W. G. (2000) J. Biol. Chem. 275, 31896-31907[Abstract/Free Full Text]
46. Ono, Y., Nakanishi, Y., Ino, Y., Niki, T., Yamada, T., Yoshimura, K., Saikawa, M., Nakajima, T., and Hirohashi, S. (1999) Cancer 85, 2315-2321[CrossRef][Medline] [Order article via Infotrieve]
47. Pyke, C., Salo, S., Ralfkiaer, E., Rømer, J., Danø, K., and Tryggvason, K. (1995) Cancer Res. 55, 4132-4139[Abstract]
48. Tani, T., Lumme, A., Linnala, A., Kivilaakso, E., Kiviluoto, T., Burgeson, R. E., Kangas, L., Leivo, I., and Virtanen, I. (1997) Am. J. Pathol. 151, 1289-1302[Abstract]
49. FibroGen, Inc. (September 15, 1998) U. S. Patent 5,807,981 9/15/98


Copyright © 2003 by The American Society for Biochemistry and Molecular Biology, Inc.